Retinopathy: Golgi and Breye join forces
Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
Fresh money for Carbios
Carbios SAS has announced a capital increase of around €122m that may grow up to €141m.
Smarter, faster, cheaper: Veeva shows how
This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries.
The innovative power of the chemical industry assembled
The Chemspec Europe 2023 provided insights into current challenges of the chemical industry, as well as the solutions it holds.
VectivBio taken over in $1bn acquisition
GI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction.
Upscaling AAV gene therapy
Biovian Oy’s second generation AAV platform will include Remedium Bio Inc.’s lead treatment candidate against Osteoarthritis.
Neurodegenerative disorders are being fought with €28m
Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
Pfizer-Seagen: Acquisition in the works
Pfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Collaboration to fight cancer
The charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.